Skip to main content

Table 2 Multivariate Cox proportional hazards analyses of clinicopathological variables and CMTC as prognostic indicators in the 3,963 overall breast cancers

From: Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations

Variables Hazard ratio 95%CI P value
ER (+) versus (-) 1.10 0.89 to 1.36 4.00E-01
Non-HER2/TN versus HER2+/TN 1.26 1.03 to 1.54 2.20E-02
Age <50 versus > = 50 0.85 0.74 to 0.96 1.10E-02
Size < =2 cm versus >2 cm 1.78 1.56 to 2.02 0.00E + 00
LN (-) versus (+) 0.68 0.60 to 0.77 8.20E-10
Grade1 versus 2 1.50 1.17 to 1.91 1.30E-03
Grade1 versus 3 1.40 1.09 to 1.81 9.80E-03
CMTC-1 versus 2 2.06 1.73 to 2.46 1.00E-15
CMTC-1 versus 3 2.01 1.62 to 2.50 3.30E-10
  1. CI, confidence interval; CMTC, ClinicoMolecular Triad Classification; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node status; TN, triple-negative.